The BSMT has confirmed that Professor Sheena Cruikshank (University of Manchester) will speak on 'From Variola to COVID-19: the Development of Modern Vaccines'. Click on this news item for the link to register for this FREE-to-attend webinar series.
The British Society for Microbial Technology event takes place on Tuesday 11 May to Friday 14 May 2021. Click on this news item for the link to register for this FREE-to-attend webinar series.
Mologic, a developer of lateral-flow and rapid diagnostics, has announced its rapid antigen self-test for SARS-CoV-2 has been selected by the Rapid Acceleration of Diagnostics (RADx) initiative launched by the US National Institutes of Health (NIH).
Avacta Group, the developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a global distribution agreement with ABCAM to sell the SARS-CoV-2 research ELISA Affimer reagents.
The BSMT Virtual Conference on COVID-19 is a FREE-to-attend event that takes place on Tuesday 11 May to Friday 14 May 2021. Click on this news item for the link to register for the webinar series.
Thermo Fisher Scientific and Artificial, a developer of flexible automation software, have announced a technology collaboration to develop an integrated and comprehensive software platform for Thermo Fisher’s standardised COVID-19 Testing Platform.
This British Society for Microbial Technology (BSMT) virtual conference, held in conjunction with media partner Pathology in Practice, on 11–14 May, will be sponsored by 22 companies.
IONTAS and FairJourney Biologics have announced the identification of neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants.
Beckman Coulter today has expanded claims for its CE-marked Access Interleukin-6 (IL-6) assay, an in vitro diagnostic test for the quantitative determination of IL-6 levels in human serum and plasma.
Aptamer Group, the developer of diagnostic and therapeutic Optimer reagents, has announced a commercial partnership with Mologic, a developer and manufacturer of lateral-flow and rapid diagnostic tests.
Additions to the programme and sponsors for this important British Society for Microbial Technology (BSMT) virtual conference, which will be held on 11–14 May, have now been released. See the following for the latest details…
The British Society for Microbial Technology (BSMT) will hold a virtual conference entitled ‘COVID-19 – The Infection Challenging the World' over four days in May. Click on this story for current details of the programme and commercial support.
Avacta Group has announced that the AffiDX SARS-CoV-2 rapid antigen lateral-flow test detects the dominant new variants of the coronavirus, known as the B117 (Kent), variant, and the D614G variant, as well as the original strain.
Roche Diagnostics has launched a rapid antigen nasal test in the UK, with millions of kits available immediately to help businesses and organisations looking to reopen as lockdown restrictions are lifted.
Bio-Rad Laboratories has announced the launch of the Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel.
The SARS-CoV-2 pandemic has resulted in a challenging work environment. This has made the development and commercialisation of vaccines, treatments and critically needed PCR-based and serological diagnostics especially challenging.
Randox has processed its 10-millionth sample for the UK’s COVID-19 National Testing Programme, making it the first Pillar 2 testing laboratory to achieve this milestone, having invested £85 million since March 2020 in facilities and equipment.
Avacta Group has received the first data for its SARS-CoV-2 rapid antigen test from ongoing clinical studies in Europe and the UK, which show excellent performance in identifying patients with an infectious viral load and no false positive results.
South African scientists warn of grave danger that disinfectant use against SARS-CoV-2 could be helping bacteria to become resistant to disinfectants.
The in vitro diagnostics industry has been at the forefront of the fight against SARS-CoV-2 and medicine’s response to cases of severe COVID-19 disease.